{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Heterotopic+Ossification",
    "query": {
      "condition": "Heterotopic Ossification"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 19,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Heterotopic+Ossification&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-07-22T03:10:47.719Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01539447",
      "title": "Influence of Naproxen on Heterotropic Bone Formation Following Hip Arthroscopy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Heterotopic Ossification"
      ],
      "interventions": [
        {
          "name": "Naproxen",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Utah",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 108,
      "start_date": "2012-01",
      "completion_date": "2022-03-16",
      "has_results": false,
      "last_update_posted_date": "2022-07-14",
      "last_synced_at": "2026-07-22T03:10:47.719Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01539447"
    },
    {
      "nct_id": "NCT03188666",
      "title": "A Study to Examine the Safety, Tolerability and Effects on Abnormal Bone Formation of REGN2477 in Patients With Fibrodysplasia Ossificans Progressiva",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Fibrodysplasia Ossificans Progressiva"
      ],
      "interventions": [
        {
          "name": "REGN2477",
          "type": "DRUG"
        },
        {
          "name": "Matching placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 44,
      "start_date": "2018-02-26",
      "completion_date": "2021-09-16",
      "has_results": true,
      "last_update_posted_date": "2022-12-02",
      "last_synced_at": "2026-07-22T03:10:47.719Z",
      "location_count": 3,
      "location_summary": "Rochester, Minnesota • Philadelphia, Pennsylvania • Nashville, Tennessee",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03188666"
    },
    {
      "nct_id": "NCT00586365",
      "title": "Naproxen for the Prevention of HO After Complex Elbow Trauma",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Heterotopic Ossification"
      ],
      "interventions": [
        {
          "name": "Naproxen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2007-10",
      "completion_date": "2010-10",
      "has_results": false,
      "last_update_posted_date": "2012-03-21",
      "last_synced_at": "2026-07-22T03:10:47.719Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00586365"
    },
    {
      "nct_id": "NCT06724562",
      "title": "IL1 Inhibition in FOP",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Fibrodysplasia Ossificans Progressiva (FOP)"
      ],
      "interventions": [
        {
          "name": "Anti-IL1 Therapy",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "6 Years to 30 Years"
      },
      "enrollment_count": 11,
      "start_date": "2025-04-01",
      "completion_date": "2027-03",
      "has_results": false,
      "last_update_posted_date": "2026-03-03",
      "last_synced_at": "2026-07-22T03:10:47.719Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06724562"
    },
    {
      "nct_id": "NCT02521792",
      "title": "In-Home Evaluation of Episodic Administration of Palovarotene in Fibrodysplasia Ossificans Progressiva (FOP) Subjects",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Fibrodysplasia Ossificans Progressiva"
      ],
      "interventions": [
        {
          "name": "Palovarotene",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Clementia Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "6 Years to 65 Years"
      },
      "enrollment_count": 6,
      "start_date": "2015-12-07",
      "completion_date": "2016-08-04",
      "has_results": true,
      "last_update_posted_date": "2020-10-19",
      "last_synced_at": "2026-07-22T03:10:47.719Z",
      "location_count": 2,
      "location_summary": "San Francisco, California • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02521792"
    },
    {
      "nct_id": "NCT02322255",
      "title": "A Natural History Study of Fibrodysplasia Ossificans Progressiva (FOP)",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Fibrodysplasia Ossificans Progressiva"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Clementia Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "Up to 65 Years"
      },
      "enrollment_count": 114,
      "start_date": "2014-12-18",
      "completion_date": "2020-04-09",
      "has_results": false,
      "last_update_posted_date": "2020-06-26",
      "last_synced_at": "2026-07-22T03:10:47.719Z",
      "location_count": 2,
      "location_summary": "San Francisco, California • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02322255"
    },
    {
      "nct_id": "NCT07024407",
      "title": "A Study of Andecaliximab in People With Spinal Cord Injury at Risk for Bone Growth Outside of the Normal Skeleton.",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Heterotopic Ossification (HO)"
      ],
      "interventions": [
        {
          "name": "Andecaliximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ashibio Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "89 Years",
        "sex": "ALL",
        "summary": "18 Years to 89 Years"
      },
      "enrollment_count": 10,
      "start_date": "2025-05-14",
      "completion_date": "2026-01",
      "has_results": false,
      "last_update_posted_date": "2025-06-17",
      "last_synced_at": "2026-07-22T03:10:47.719Z",
      "location_count": 1,
      "location_summary": "Denver, Colorado",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07024407"
    },
    {
      "nct_id": "NCT05394116",
      "title": "A Study to Assess Safety, Tolerability and Efficacy of Garetosmab Versus Placebo Administered Intravenously (IV) in Adult Participants With Fibrodysplasia Ossificans Progressiva (FOP)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Fibrodysplasia Ossificans Progressiva"
      ],
      "interventions": [
        {
          "name": "Garetosmab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 63,
      "start_date": "2022-11-21",
      "completion_date": "2029-02-27",
      "has_results": false,
      "last_update_posted_date": "2026-07-17",
      "last_synced_at": "2026-07-22T03:10:47.719Z",
      "location_count": 2,
      "location_summary": "Los Angeles, California • Nashville, Tennessee",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05394116"
    },
    {
      "nct_id": "NCT06508021",
      "title": "A Study of Andecaliximab in Participants With Fibrodysplasia Ossificans Progressiva (FOP)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Fibrodysplasia Ossificans Progressiva"
      ],
      "interventions": [
        {
          "name": "Andecaliximab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ashibio Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "2 Years and older"
      },
      "enrollment_count": 92,
      "start_date": "2024-10-25",
      "completion_date": "2029-02-04",
      "has_results": false,
      "last_update_posted_date": "2025-10-14",
      "last_synced_at": "2026-07-22T03:10:47.719Z",
      "location_count": 3,
      "location_summary": "San Francisco, California • Rochester, Minnesota • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06508021"
    },
    {
      "nct_id": "NCT02190747",
      "title": "An Efficacy and Safety Study of Palovarotene to Treat Preosseous Flare-ups in FOP Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Fibrodysplasia Ossificans Progressiva"
      ],
      "interventions": [
        {
          "name": "Palovarotene",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Clementia Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "6 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2014-07-14",
      "completion_date": "2016-05-23",
      "has_results": true,
      "last_update_posted_date": "2021-02-16",
      "last_synced_at": "2026-07-22T03:10:47.719Z",
      "location_count": 2,
      "location_summary": "San Francisco, California • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02190747"
    }
  ]
}